Predict your next investment

Corporation
HEALTHCARE | Drug Development
aduro.com

See what CB Insights has to offer

Founded Year

2000

Stage

IPO | IPO

Total Raised

$173.19M

Date of IPO

4/15/2015

Market Cap

0.23B

Revenue

$0000 

About Aduro BioTech

Aduro is advancing multiple therapeutic and prophylactic vaccines for cancer and infectious diseases based on its attenuated Listeria monocytogenes vaccine platforms. The company is also advancing a new program towards clinical evaluation that utilizes targeted small molecule immune modulators that have broad application for vaccine design. The company's Listeria platform has been validated by publications that illustrate the platform's combination of safety and potency.

Aduro BioTech Headquarter Location

740 Heinz Ave

Berkeley, California, 94710,

United States

510-848-4400

Latest Aduro BioTech News

Boundless Bio Appoints Jennifer Lew to its Board of Directors

Jan 12, 2022

-Ms. Lew is a senior biotech executive bringing more than 15 years of strategic financial and operational experience to her role on the Board of Directors- January 05, 2022 08:00 AM Eastern Standard Time SAN DIEGO--( BUSINESS WIRE )-- Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that Jennifer Lew has been appointed to its Board of Directors and will serve as chairperson of the Audit Committee. “I am pleased to welcome Jen to our Board of Directors,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Jen is a senior biotech executive with a depth of expertise in financial operations and financing, investor relations, and strategic planning. Her demonstrated leadership in financial and strategic matters complements the notable skills and experience of our current directors and will be a valuable asset to our Board as Boundless Bio continues to grow and advance its pipeline.” “I am delighted to join Boundless Bio and other members of the Board during this exciting time for the Company,” said Ms. Lew. “I look forward to supporting the executive team in the execution of its business plans and strategy to bring forward a pipeline of innovative therapies directed against ecDNA.” Ms. Lew currently serves as Executive Vice President and Chief Financial Officer of Annexon Biosciences, where she led the company to completion of its successful initial public offering in 2020. Ms. Lew previously served as Chief Financial Officer for Aduro Biotech, Inc., where she played a key leadership role in financial and strategic matters, including Aduro’s initial public offering. Prior to Aduro, Ms. Lew held various roles of increasing responsibility at Dynavax Technologies Corporation and QRS Corporation. Ms. Lew began her career in the audit practice at Ernst & Young. She earned a BA in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status). About Boundless Bio Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers. For more information, visit www.boundlessbio.com .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aduro BioTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aduro BioTech is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,238 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aduro BioTech Patents

Aduro BioTech has filed 63 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/1/2017

8/24/2021

Immune system, Clusters of differentiation, Immunology, Monoclonal antibodies, Molecular biology

Grant

Application Date

7/1/2017

Grant Date

8/24/2021

Title

Related Topics

Immune system, Clusters of differentiation, Immunology, Monoclonal antibodies, Molecular biology

Status

Grant

Aduro BioTech Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aduro BioTech Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.